Attentive Science

Executive Summary

Attentive Science is a San Francisco-based contract research organization (CRO) founded in 2020, leveraging AI and machine learning to accelerate preclinical drug development. The company offers specialized services in pharmacokinetics, toxicology, and safety pharmacology for biotech, pharma, animal health, and agrochemical clients. By integrating digital health tools and AI-driven analytics, Attentive Science aims to improve the efficiency and predictive accuracy of preclinical studies, reducing time and cost for drug developers. The CRO market is large and growing, with increasing outsourcing trends and demand for innovative preclinical solutions. Attentive Science's niche focus on AI-enhanced research positions it to capture a share of this market, particularly among small and mid-sized biotechs seeking smarter CRO partnerships. While still early-stage and privately funded, the company has the potential to differentiate itself through technology-driven service offerings and expand its client base as validation accrues.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Mid-Sized Biotech40% success
• Q4 2026Publication of Validation Study Demonstrating AI-Enhanced Preclinical Accuracy50% success
• H2 2026Series A Funding Round to Scale Operations and AI Platform35% success